전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,373 programs
AntibodyLimited DatastaleAbGenomics B.V Taiwan BranchPhase 2

Neihulizumab Treatment (Neihulizumab Treatment)

Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Steroid-refractoryaGvHDSubsequen+1
Trials 1Status Discontinued
AntibodyLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Breast Cancer; Triple Negative Breast Cancer (TNBC) · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleSwiss Cancer InstitutePhase 2

durvalumab (Imfinzi, Neoadjuvant and adjuvant durvalumab)

Urothelial Cancer · Urothelial Cancer

#UrothelialCancer#Antibody#Phase2#monoclonal-antibody#Swiss
Trials 1Status Active
AntibodyLimited DatastaleSeoul National University Hospi…Preclinical

atezolizumab (Tecentriq, Neoadjuvant atezolizumab)

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Preclinical#monoclonal-antibody#Seoul
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Neoadjuvant chemotherapy combined with Toripalimab (Neoadjuvant chemotherapy combined with Toripalimab)

TNBC, Triple Negative Breast Cancer · TNBC, Triple Negative Breast Cancer

#TNBCTripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#TNBC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#monoclonal-antibody#OvarianCancerStageIV+1
Trials 1Status Active
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant ipilimumab (Neoadjuvant ipilimumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

Malignant Melanoma Stage III · Malignant Melanoma Stage III

#MalignantMelanomaStageIII#Antibody#Phase3#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

nivolumab (Opdivo, Neoadjuvant nivolumab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

Neoadjuvant relatlimab (Neoadjuvant relatlimab)

Renal Cell Carcinoma · Renal Cell Carcinoma

#RenalCellCarcinoma#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab)

HR Positive/HER2 Low Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HRPositive+2
Trials 1Status Recruiting
AntibodyLimited DatastaleBiocadPhase 3

Netakimab (Netakimab)

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#monoclonal-antibody#Biocad
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

New donor-derived CD7 CAR T-cell (New donor-derived CD7 CAR T-cell)

T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

Newly matched donor-derived CD5 CAR T-cells (Newly matched donor-derived CD5 CAR T-cells)

T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting
AntibodyLimited DatastaleY-mAbs TherapeuticsPhase 2

Nivatrotamab (Nivatrotamab)

SCLC · SCLC

#SCLC#Antibody#Phase2#monoclonal-antibody#Y-mAbs
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePreclinical

No Rituximab (No Rituximab)

Renal Transplant Rejection · Renal Transplant Rejection

#RenalTransplantRejection#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerRecurrent+1
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting

90 / 119 pages

← PreviousNext →